Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis
Authors
Keywords
Ferroptosis, Disulfiram, Hepatocellular carcinoma, Oxidative stress, Sorafenib
Journal
Redox Biology
Volume 46, Issue -, Pages 102122
Publisher
Elsevier BV
Online
2021-08-31
DOI
10.1016/j.redox.2021.102122
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Activation of anti-oxidant Keap1/Nrf2 pathway modulates efficacy of dihydroartemisinin-based monotherapy and combinatory therapy with ionizing radiation
- (2021) Sina Bader et al. FREE RADICAL BIOLOGY AND MEDICINE
- GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis
- (2021) Qiujie Wang et al. Cell Death & Disease
- DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism
- (2021) Jing Du et al. Cell Death & Disease
- Identification of Frataxin as a regulator of ferroptosis
- (2020) Jing Du et al. Redox Biology
- Disulfiram/Copper Induces Antitumor Activity against Both Nasopharyngeal Cancer Cells and Cancer-Associated Fibroblasts through ROS/MAPK and Ferroptosis Pathways
- (2020) Yiqiu Li et al. Cancers
- Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
- (2020) Zhong-jie Li et al. ACTA PHARMACOLOGICA SINICA
- The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
- (2020) Jimin Yuan et al. Journal of Hematology & Oncology
- Disulfiram, a Ferroptosis Inducer, Triggers Lysosomal Membrane Permeabilization by Up-Regulating ROS in Glioblastoma
- (2020) Chen Qiu et al. OncoTargets and Therapy
- Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis
- (2020) Yanchun Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Drug repurposing in oncology
- (2020) Maria Frantzi et al. LANCET ONCOLOGY
- The Nrf2 induction prevents ferroptosis in Friedreich's Ataxia
- (2020) Piergiorgio La Rosa et al. Redox Biology
- The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
- (2019) Kirill Bersuker et al. NATURE
- Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells
- (2018) Yuko Murakami et al. BMC CANCER
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis
- (2018) Irina Ingold et al. CELL
- The Development of the Concept of Ferroptosis
- (2018) Tal Hirschhorn et al. FREE RADICAL BIOLOGY AND MEDICINE
- Role of Mitochondria in Ferroptosis
- (2018) Minghui Gao et al. MOLECULAR CELL
- DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin
- (2018) Jing Du et al. FREE RADICAL BIOLOGY AND MEDICINE
- Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways
- (2017) Yi Li et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
- (2017) Zdenek Skrott et al. NATURE
- Oncogene-Selective Sensitivity to Synchronous Cell Death following Modulation of the Amino Acid Nutrient Cystine
- (2017) Ioannis Poursaitidis et al. Cell Reports
- The Roles of NRF2 in Modulating Cellular Iron Homeostasis
- (2017) Michael John Kerins et al. ANTIOXIDANTS & REDOX SIGNALING
- Iron and cancer: recent insights
- (2016) David H. Manz et al. Annals of the New York Academy of Sciences
- Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis
- (2016) Xiaofang Sun et al. HEPATOLOGY
- ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
- (2016) Sebastian Doll et al. Nature Chemical Biology
- Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells
- (2015) Xiaofang Sun et al. HEPATOLOGY
- Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners
- (2014) Tetsuhiro Chiba et al. PLoS One
- Phosphorylation of p62 Activates the Keap1-Nrf2 Pathway during Selective Autophagy
- (2013) Yoshinobu Ichimura et al. MOLECULAR CELL
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
- (2012) Scott J. Dixon et al. CELL
- Trigonelline: A Plant Alkaloid with Therapeutic Potential for Diabetes and Central Nervous System Disease
- (2012) J. Zhou et al. CURRENT MEDICINAL CHEMISTRY
- Hepatocellular Carcinoma
- (2011) Hashem B. El-Serag NEW ENGLAND JOURNAL OF MEDICINE
- Disulfiram Treatment Facilitates Phosphoinositide 3-Kinase Inhibition in Human Breast Cancer Cells In vitro and In vivo
- (2010) H. Zhang et al. CANCER RESEARCH
- Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma
- (2010) Brian W. Morrison et al. MELANOMA RESEARCH
- Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth
- (2010) Jianqing Lin et al. PROSTATE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More